Literature DB >> 24263384

Pupillary response to sparse multifocal stimuli in multiple sclerosis patients.

E N Ali1, T Maddess2, A C James2, C Voicu2, C J Lueck3.   

Abstract

OBJECTIVES: The objective of this paper is to investigate the pattern of abnormalities and establish the diagnostic power of multifocal objective pupil perimetry (mfPOP) in multiple sclerosis (MS).
METHODS: A prospective study enrolling 35 normal (47.9 ± 16.8 years, 22 females) and 85 MS subjects (49.8 ± 11.3 years, 62 females; 72 relapsing-remitting (RR), and 13 primary or secondary progressives (PorS)). EDSS scores for the RR and PorS groups were 3.53 ± 1.04 (mean ± SD), and 5.9 ± 1.43, respectively. mfPOP responses were obtained from 44 regions/visual field. Each region was analysed according to response time-to-peak and standardised amplitude (AmpStd). Predictive power was measured by percentage area under the receiver operator curve (%AUC).
RESULTS: mfPOP responses showed a significant reduction of 0.69 ± 0.04 dB (mean ± SE) in AmpStd and significantly delayed time-to-peak of 25.95 ± 0.89 ms (mean ± SE) in MS subjects compared to control subjects (p<0.001). %AUC was greater for time-to-peak than AmpStd both for RR and PorS patients. Diagnostic power followed the EDSS scores but not a history of optic neuritis.
CONCLUSIONS: mfPOP is well tolerated and potentially has a role in the diagnosis and assessment of patients with MS.
© The Author(s) 2013.

Entities:  

Keywords:  Multiple sclerosis; clinical neurophysiology; diagnostic test assessment; optic neuritis; perimetry; pupils

Mesh:

Year:  2013        PMID: 24263384     DOI: 10.1177/1352458513512708

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  8 in total

1.  Multifocal visual evoked potentials and contrast sensitivity correlate with ganglion cell-inner plexiform layer thickness in multiple sclerosis.

Authors:  Divya Narayanan; Han Cheng; Rosa A Tang; Laura J Frishman
Journal:  Clin Neurophysiol       Date:  2018-11-13       Impact factor: 3.708

2.  Recovery dynamics of multifocal pupillographic objective perimetry from tropicamide dilation.

Authors:  Bhim Bahadur Rai; Faran Sabeti; Corinne F Carle; Emilie M F Rohan; Özge Saraç; Joshua van Kleef; Ted Maddess
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-13       Impact factor: 3.117

3.  Objective perimetry and progression of multiple sclerosis.

Authors:  Ted Maddess; Corinne F Carle; Emilie M F Rohan; Jonathan Baird-Gunning; Josh P van Kleef; Christian J Lueck
Journal:  eNeurologicalSci       Date:  2022-10-08

4.  Assessing migraine patients with multifocal pupillographic objective perimetry.

Authors:  Eman N Ali; Corinne F Carle; Christian J Lueck; Maria Kolic; Ted Maddess
Journal:  BMC Neurol       Date:  2021-05-26       Impact factor: 2.474

5.  Comparing multifocal pupillographic objective perimetry (mfPOP) and multifocal visual evoked potentials (mfVEP) in retinal diseases.

Authors:  Faran Sabeti; Andrew C James; Corinne F Carle; Rohan W Essex; Andrew Bell; Ted Maddess
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

6.  Retinotopic effects of visual attention revealed by dichoptic multifocal pupillography.

Authors:  Yanti Rosli; Corinne Frances Carle; Yiling Ho; Andrew Charles James; Maria Kolic; Emilie Marie Françoise Rohan; Ted Maddess
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

7.  Abnormal Dynamic Pupillometry Relates to Neurologic Disability and Retinal Axonal Loss in Patients With Multiple Sclerosis.

Authors:  Gulfidan Bitirgen; Zehra Akpinar; Huseyin B Turk; Rayaz A Malik
Journal:  Transl Vis Sci Technol       Date:  2021-04-01       Impact factor: 3.283

8.  Clustered Volleys Stimulus Presentation for Multifocal Objective Perimetry.

Authors:  Corinne F Carle; Andrew C James; Faran Sabeti; Maria Kolic; Rohan W Essex; Chris Shean; Rhiannon Jeans; Aiasha Saikal; Alice Licinio; Ted Maddess
Journal:  Transl Vis Sci Technol       Date:  2022-02-01       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.